01—Abstract
Summary
Summary of the 8-K filed October 31, 2025. Cited figures are marked; the original filing is the authoritative source.
AbbVie reported third-quarter 2025 results that were mixed at the headline level: GAAP diluted EPS fell 88.6% to $0.10a and adjusted diluted EPS fell 38.0% to $1.86, but both figures absorbed a $1.50-per-share charge from acquired IPR&D and milestones expense.
Underlying top-line momentum was solid. Net revenues rose 9.1% reported (8.4% operational) to $15.776 billionb, led by Skyrizi (+46.8% to $4.708 billion) and Rinvoq (+35.3% to $2.184 billion), which more than offset the steep decline in Humira (-55.4% to $993 million) as biosimilar erosion continues. Neuroscience grew 20.2% to $2.841 billion, while Oncology was roughly flat and Aesthetics declined 3.7%.
Management raised full-year 2025 adjusted diluted EPS guidance to $10.61c–$10.65 from $10.38–$10.58, even after absorbing $2.05 per share of year-to-date IPR&D and milestone charges. The guidance excludes any future IPR&D or milestone charges, which management says cannot be reliably forecast, so the range is effectively a floor relative to deal activity in Q4. The board also approved a 5.5% increase in the quarterly dividend to $1.73 per share, payable February 17, 2026, extending AbbVie's record of dividend growth.
The filing also flagged several pipeline and regulatory milestones: FDA approval of an expanded Rinvoq indication in ulcerative colitis and Crohn's disease, positive Phase 3 results in alopecia areata and vitiligo, a head-to-head win over Humira in rheumatoid arthritis, an NDA for tavapadon in Parkinson's disease, and a BLA for pivekimab sunirine. Quarterly GAAP results were also weighed down by an $847 milliond impairment on Resonic and Durysta intangible assets and a $776 million change in fair value of contingent consideration, and the GAAP tax rate of 73.7% was distorted by these items. Investors should focus on the durability of Skyrizi and Rinvoq growth against the Humira decline, and on the recurring nature of IPR&D charges.
02—Key points
Key Highlights
- GAAP diluted EPS of $0.10 (down 88.6%) and adjusted diluted EPS of $1.86 (down 38.0%), both including a $1.50/share unfavorable impact from acquired IPR&D and milestones expense of $2.7 billion
- Net revenues of $15.776 billion, up 9.1% reported (8.4% operational), with Skyrizi (+46.8% to $4.708B) and Rinvoq (+35.3% to $2.184B) driving growth as Humira fell 55.4% to $993M
- Neuroscience grew 20.2% to $2.841B (Vraylar, Botox Therapeutic, Qulipta, and Ubrelvy all growing), while Oncology was flat at $1.682B (Imbruvica down 14.8%) and Aesthetics declined 3.7% to $1.193B
- Full-year 2025 adjusted diluted EPS guidance raised to $10.61–$10.65 from $10.38–$10.58, inclusive of $2.05/share in year-to-date IPR&D charges and excluding any future IPR&D or milestone charges
- Quarterly dividend increased 5.5% to $1.73/share from $1.64, payable February 17, 2026; AbbVie has raised its dividend more than 330% since 2013
- Q3 GAAP results included an $847M intangible asset impairment (Resonic and Durysta) and a $776M change in fair value of contingent consideration, with a GAAP tax rate of 73.7% versus an adjusted rate of 24.5%
- Pipeline progress included Rinvoq FDA label expansion in UC/Crohn's, positive Phase 3 data in alopecia areata and vitiligo, a superiority win over Humira in RA, and new filings for tavapadon (NDA) and pivekimab sunirine (BLA)
03—Questions
Frequently Asked Questions
Why did GAAP and adjusted EPS fall so sharply if revenue grew?
The decline was driven by acquired IPR&D and milestones expense of $2.68 billion in the quarter (versus $82 million a year earlier), which reduced EPS by $1.50 on both GAAP and adjusted bases. Higher intangible asset impairments ($847M), contingent consideration fair value changes ($776M), and acquisition costs also weighed on GAAP results, while higher R&D and cost of products sold offset revenue gains.
Is the raised 2025 EPS guidance a true improvement?
Partly. The raised range of $10.61–$10.65 already includes $2.05 per share of IPR&D and milestone charges incurred through Q3, meaning underlying expectations were effectively strengthened. However, the guidance excludes any future IPR&D or milestone charges, so Q4 results could be lower if AbbVie completes additional deals or milestone payments.
How significant is the Humira decline for AbbVie's growth outlook?
Humira's sales fell 55.4% year over year to $993 million as biosimilar competition continues, reducing its share of the portfolio sharply. Growth from Skyrizi and Rinvoq, which together generated $6.9 billion in the quarter, has more than offset this erosion, but the company remains dependent on the continued momentum of these newer immunology products.
What does the 5.5% dividend increase signal to shareholders?
The increase to $1.73 per quarter (from $1.64) reflects management's confidence in cash generation and the business outlook. AbbVie is a member of the S&P Dividend Aristocrats Index, and the increase continues a long track record of annual dividend growth, though investors should weigh it against heavy acquisition-related spending and net interest expense of $667 million in the quarter.
What pipeline developments could affect future revenue?
Key developments include FDA approval of an expanded Rinvoq indication for ulcerative colitis and Crohn's disease, positive Phase 3 results for Rinvoq in severe alopecia areata and non-segmental vitiligo, a head-to-head win over Humira in rheumatoid arthritis, an NDA submission for tavapadon in Parkinson's disease, and a BLA for pivekimab sunirine in BPDCN. Approvals and launches of these candidates would broaden AbbVie's growth drivers beyond Skyrizi and Rinvoq, though regulatory outcomes remain uncertain.
04—Continue